Document Detail


Effects of imidapril on left ventricular mass in chronic hemodialysis patients.
MedLine Citation:
PMID:  16778332     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Left ventricular hypertrophy is considered to be a major cardiovascular risk factor in hemodialysis patients. Not only high blood pressure but also humoral factors such as angiotensin II and aldosterone are thought to contribute to the increase in left ventricular mass. We examined the effects of an angiotensin converting enzyme (ACE) inhibitor, imidapril, on left ventricular mass in patients with end-stage renal diseases on maintenance hemodialysis. Thirty patients on chronic hemodialysis were randomly divided into 2 groups of 15 patients each and given placebo or 2.5 mg imidapril once daily for 6 months. Before and after the 6-month period, left ventricular mass was evaluated by echocardiography, and circulating factors of the renin-angiotensin-aldosterone system were measured. Background characteristics such as age, gender ratio, causes of renal failure, duration of hemodialysis, body mass index and pre-dialysis blood pressure were comparable between the placebo and the imidapril groups. Systolic and diastolic blood pressures were not significantly changed in either group during the study period. In the imidapril group, serum ACE was reduced (12 +/- 1 to 5 +/- 2 U/l, p < 0.01) and plasma renin activity was increased (3.3 +/- 0.8 to 8.1 +/- 3.2 ng/ml/h, p < 0.01), but plasma angiotensin II and aldosterone were not significantly changed after 6 months (13 +/- 3 to 17 +/- 3 pg/ml and 365 +/- 125 to 312 +/- 132 pg/ml, respectively). On the other hand, left ventricular mass index was significantly decreased in the imidapril group (132 +/- 10 to 109 +/- 6 g/m2, p < 0.05) but was unchanged in the placebo group (129 +/- 6 to 126 +/- 5 g/m2). These results suggest that an ACE inhibitor reduces left ventricular mass in hemodialysis patients by a mechanism that is independent of changes in blood pressure.
Authors:
Nobuko Matsumoto; Toshihiko Ishimitsu; Atsushi Okamura; Hitoshi Seta; Masaki Takahashi; Hiroaki Matsuoka
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  29     ISSN:  0916-9636     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-06-16     Completed Date:  2006-07-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  253-60     Citation Subset:  IM    
Affiliation:
Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University, Tochigi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*,  adverse effects
Blood Pressure / drug effects
Body Weight / drug effects
Echocardiography
Female
Humans
Hypertension, Renal / drug therapy*,  etiology
Hypertrophy, Left Ventricular / etiology,  prevention & control*,  ultrasonography
Imidazolidines / administration & dosage*,  adverse effects
Kidney Failure, Chronic / complications*,  therapy
Male
Middle Aged
Placebos
Renal Dialysis*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Imidazolidines; 0/Placebos; 89396-94-1/imidapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare misse...
Next Document:  Characteristics of young-onset hypertension identified by targeted screening performed at a universi...